-
, molecular, behavioural and environmental determinants of non-communicable diseases, ultimately benefiting patients and society. The Centre owns exceptionally rich genetic and molecular (especially proteomic
-
, molecular, behavioural and environmental determinants of non-communicable diseases, ultimately benefiting patients and society. The Centre owns exceptionally rich genetic and molecular (especially proteomic
-
, molecular, behavioural and environmental determinants of non-communicable diseases, ultimately benefiting patients and society. The Centre owns exceptionally rich genetic and molecular (especially proteomic
-
Learning, at the Centre of Genomics in the research group of Craig Glastonbury . The post holder will be responsible for leading large-scale digital pathology, spatial transcriptomic and genetic analyses
-
, exploring how developmental cues intersect with genetic lesions to initiate leukaemia. Key methodologies will include CRISPR/Cas9-mediated gene editing, high-end flow cytometry, and single-cell multiomics
-
that regulate B cell activation, antibody production and their genetic variability. We use a wide range of immunological and genomic assays to study B cell biology, antibody diversity and variation in the human
-
BAs. The project focuses on two fundamental and complementary BA modifications: de‐conjugation and the recently discovered re‐conjugation of BAs with different amino acids. A not exhaustive list of
-
list of questions we aim to tackle are: Why are only some bacteria capable of performing one or both processes? Under which environmental conditions do organisms that can execute both modifications
-
. the genetic `capabilities’) is distributed and maintained across community members, and how these distributions of functions shape ecosystem-level properties. Answering these questions in a host-associated